Blennow, Kaj
University of Science and Technology of China · Sorbonne Université · Institut des Sciences Moléculaires · Pitié-Salpêtrière Hospital · UK Dementia Research Institute · Institut du Cerveau · UCL Queen Square Institute of Neurology · University College London
317 papers on CoChatORCID 0000-0002-1890-4193
Most cited papers
- Verified
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 1,070
- Verified
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 1,051
- Verified
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 1,048
- Verified
A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease
Wightman, D. P., Jansen, I. E., Savage, J. E., Shadrin, A. A., Bahrami, S., Holland, D., Rongve, A., Børte, S., Winsvold, B. S., Drange, O. K., et al. (2021) · Nature Genetics
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 1,011
- Verified
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 1,000
- Verified
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. (2017) · Nature Communications
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 911
- Verified
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 884
- Verified
An 18-Year Follow-up of Overweight and Risk of Alzheimer Disease
Gustafson, D., Rothenberg, E., Blennow, K., Steen, B., & Skoog, I. (2003) · Archives of Internal Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 811
- Verified
CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 808
- Verified
tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 789
- Verified · note
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis
Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology
Multiple Sclerosis Research StudiesCerebrospinal fluid and hydrocephalus
Cited by 764
- Verified
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 761
- Verified
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 753
- Verified
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
Kuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM)
Multiple Sclerosis Research StudiesAdvanced Biosensing Techniques and Applications
Cited by 740
- Verified
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 726
- Verified
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 725
- Verified
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 724
- Verified
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 719
- Verified
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 716
- Verified
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 701
- Verified
CSF and blood biomarkers for Parkinson's disease
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology
Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research
Cited by 673
- Verified
The Neuropathology and Neurobiology of Traumatic Brain Injury
Blennow, K., Hardy, J., & Zetterberg, H. (2012) · Neuron
Traumatic Brain Injury ResearchTraumatic Brain Injury and Neurovascular Disturbances
Cited by 669
- Verified
Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 660
- Verified
Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 638
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free